title: Deferiprone versus desferrioxamine in thalassaemia, and T2* validation and utility.
authors.forename: G M
authors.initials: GM
authors.lastname: Brittenham
authors.forename: D G
authors.initials: DG
authors.lastname: Nathan
authors.forename: N F
authors.initials: NF
authors.lastname: Olivieri
authors.forename: M J
authors.initials: MJ
authors.lastname: Pippard
authors.forename: D J
authors.initials: DJ
authors.lastname: Weatherall
mesh_terms: D009202:Cardiomyopathies / Q000401:mortality; D000077543:Deferiprone; D003676:Deferoxamine / Q000627:therapeutic use*; D006801:Humans; D007502:Iron Chelating Agents / Q000627:therapeutic use*; D011728:Pyridones / Q000627:therapeutic use*; D015203:Reproducibility of Results; D017086:beta-Thalassemia / Q000188:drug therapy* / Q000401:mortality
chemical_list: D007502:Iron Chelating Agents; D011728:Pyridones; D000077543:Deferiprone; D003676:Deferoxamine